February 8, 2012

Integra LifeSciences Announces Launch of the Integra(R) Allograft Wedge System for Extremity Reconstruction

PLAINSBORO, N.J., Feb. 8, 2012 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the introduction of Integra® Allograft Wedge System, which consists of simple pre-cut allograft wedges for both Evans and Cotton osteotomies and a dedicated instrumentation set that is designed to provide a method of assessing osteotomy space to aid in the selection of the appropriate Integra® Allograft Wedge implant.

Osteotomies are procedures in which surgeons realign or remove a segment of bone located near a damaged joint to help correct deformities, typically in the foot. Integra® Allograft Wedge is designed to provide bone grafting material for osteotomy corrections. The Integra® Allograft Wedge is processed from human cancellous bone, sterilized through the BioCleanse® Tissue Sterilization Process and terminally sterilized using a validated method to achieve a Sterility Assurance Level (SAL) of 10-6. The wedge provides a natural scaffold for bone growth, as well as biologic stability and structural support for deformity corrections. It also eliminates significant harvest site morbidity that may result from autograft removal. Integra will feature the implant at the American Academy of Orthopaedic Surgeons Annual Meeting, February 7-11, 2012 in San Francisco, California.

"Integra® Allograft Wedge System offers four sizes (6, 8, 10 and 12mm), which gives surgeons a significant addition to their treatment options and helps limit uncertainty by accommodating a patient's unique surgical needs," said Bill Weber, Vice President and General Manager, Integra Extremity Reconstruction.

The Integra® Allograft Wedge System is distributed through Integra's Extremity Reconstruction sales organization, which focuses on lower extremity fixation, upper extremity fixation, tendon protection, peripheral nerve repair/protection and wound repair.

Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care.  Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results.  Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2010 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

BioCleanse is a registered trademark of RTI Biologics, Inc

CONTACT: Integra LifeSciences Holdings Corporation

         

         Gianna Sabella

         Director, Corporate Communications

         (609) 936-2389

         gianna.sabella@integralife.com


Close window | Back to top

Copyright 2014 Integra LifeSciences Holdings Corporation